Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BCG is used experimentally as a vaccine against tuberculosis (TB), induced by Mycobacterium bovis, in cattle (bTB). However, the efficacy of BCG is variable in humans, cattle and guinea pigs. An adenoviral vector expressing Antigen 85A (Ad5Ag85A) has enhanced protection against TB in mice when used in combination with BCG for prime-boost experiments. However, the route of immunisation affects the degree of protection seen. This work examines the immunogenicity of a new vectored vaccine (Ad5-TBF) that expresses Ag85A, Rv0287, Rv0288 and Rv0251c to explore the effects of dose of adenoviral boost and route of inoculation on immunogenicity. We found that 2×10(9) infectious units (iu) delivered intradermally conferred the most consistent and strongest responses of the different regimes tested.

Original publication




Journal article


Vet Immunol Immunopathol

Publication Date





208 - 213


Adenovirus, Mycobacteria, Route of immunisation, Tuberculosis, Vaccine, Adenoviridae, Animals, Antigens, Bacterial, BCG Vaccine, Cattle, Dose-Response Relationship, Immunologic, Genetic Vectors, Immunization Schedule, Immunization, Secondary, Injections, Intradermal, Male, Mycobacterium bovis, Recombinant Fusion Proteins, Tuberculosis, Bovine